ICAS
ENTA icon

Investors Capital Advisory Services’s Enanta Pharmaceuticals ENTA Stock Holding History

Investors Capital Advisory Services’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-6,350
Closed -$229K – 722
2015
Q3 		$229K Sell
6,350
-500
-7% -$21.5K 0.05% 540
2015
Q2 		$308K Buy
6,850
+210
+3% +$8.17K 0.06% 462
2015
Q1 		$203K Buy
6,640
+1,450
+28% +$56.4K 0.04% 610
2014
Q4 		$263K Buy
+5,190
New +$232K 0.05% 485

Other funds holding ENTA

ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Investors Capital Advisory Services's ENTA Position: Q4 2015 in Review

Investors Capital Advisory Services sold out of Enanta Pharmaceuticals (ENTA) in Q4 2015, closing a stake of 6,350 shares — an estimated $229K sold.

Investors Capital Advisory Services first reported a position in ENTA in Q4 2014 and held it in 4 quarters. The position peaked at $308K in Q2 2015. 136 funds tracked by Wall St. Rank hold ENTA as of Q4 2015.

  • Investors Capital Advisory Services reported no remaining Enanta Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Investors Capital Advisory Services sold 6,350 Enanta Pharmaceuticals shares in Q4 2015, an estimated $229K.
  • Investors Capital Advisory Services first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 4 quarters.
  • Investors Capital Advisory Services's Enanta Pharmaceuticals position peaked at $308K in Q2 2015.
  • 136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2015.

Based on Investors Capital Advisory Services's 13F filing for Q4 2015, filed 8 Feb 2016.